Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Other Accumulated Expenses (2020 - 2025)

Cardiff Oncology's Other Accumulated Expenses history spans 5 years, with the latest figure at $287000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 24.78% year-over-year to $287000.0; the TTM value through Dec 2025 reached $287000.0, up 24.78%, while the annual FY2025 figure was $287000.0, 24.78% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $287000.0 at Cardiff Oncology, down from $419000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $419000.0 in Q1 2025 and bottomed at $8000.0 in Q3 2022.
  • The 4-year median for Other Accumulated Expenses is $136000.0 (2021), against an average of $168000.0.
  • The largest annual shift saw Other Accumulated Expenses crashed 80.95% in 2022 before it grew 24.78% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $42000.0 in 2021, then plummeted by 80.95% to $8000.0 in 2022, then surged by 2775.0% to $230000.0 in 2024, then rose by 24.78% to $287000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Other Accumulated Expenses are $287000.0 (Q4 2025), $419000.0 (Q1 2025), and $230000.0 (Q4 2024).